Tvardi Therapeutics (NASDAQ:TVRD) Lowered to Strong Sell Rating by Wall Street Zen

Posted by Brenda Bartman on Jul 19th, 2026

Wall Street Zen cut shares of Tvardi Therapeutics (NASDAQ:TVRD – Free Report) to a strong sell rating in a research note released on Saturday.

TVRD has been the subject of a number of other reports. UBS Group raised shares of Tvardi Therapeutics to an “outperform” rating and set a $10.00 price target for the company in a research report on Wednesday, July 8th. Raymond James Financial upgraded shares of Tvardi Therapeutics from a “market perform” rating to an “outperform” rating and set a $10.00 price objective for the company in a research note on Wednesday, July 8th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tvardi Therapeutics in a report on Wednesday, July 8th. Piper Sandler upgraded Tvardi Therapeutics from a “neutral” rating to an “overweight” rating and set a $13.00 target price on the stock in a research report on Wednesday, July 8th. Finally, HC Wainwright initiated coverage on Tvardi Therapeutics in a report on Monday, June 8th. They issued a “buy” rating and a $9.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $19.67.

Check Out Our Latest Analysis on Tvardi Therapeutics

Tvardi Therapeutics Trading Up 3.9%

TVRD stock opened at $3.20 on Friday. Tvardi Therapeutics has a twelve month low of $1.50 and a twelve month high of $43.65. The company’s 50 day moving average is $3.04 and its two-hundred day moving average is $3.50. The stock has a market cap of $30.02 million, a P/E ratio of -1.03 and a beta of 0.39.

Tvardi Therapeutics (NASDAQ:TVRD – Get Free Report) last issued its quarterly earnings data on Friday, May 8th. The company reported ($0.73) earnings per share for the quarter, missing the consensus estimate of ($0.65) by ($0.08). On average, equities research analysts predict that Tvardi Therapeutics will post -2.32 earnings per share for the current year.

Institutional Trading of Tvardi Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. raised its holdings in Tvardi Therapeutics by 5.2% during the third quarter. Vanguard Group Inc. now owns 419,167 shares of the company’s stock worth $16,335,000 after purchasing an additional 20,757 shares in the last quarter. American Financial Group Inc. purchased a new stake in Tvardi Therapeutics in the 4th quarter valued at approximately $962,000. Vestal Point Capital LP purchased a new stake in Tvardi Therapeutics in the 3rd quarter valued at approximately $6,508,000. Geode Capital Management LLC boosted its holdings in Tvardi Therapeutics by 6.2% in the 4th quarter. Geode Capital Management LLC now owns 157,133 shares of the company’s stock valued at $676,000 after purchasing an additional 9,214 shares in the last quarter. Finally, State Street Corp increased its position in Tvardi Therapeutics by 83.7% during the 4th quarter. State Street Corp now owns 115,501 shares of the company’s stock worth $497,000 after purchasing an additional 52,637 shares during the period. Hedge funds and other institutional investors own 44.66% of the company’s stock.

About Tvardi Therapeutics

(Get Free Report)

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.